Trial Profile
REACTION: A Phase II Study of Etoposide and Cis/Carboplatin With or Without Pembrolizumab in Untreated Extensive Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Etoposide
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Acronyms REACTION
- 08 Dec 2023 Status changed from active, no longer recruiting to completed.
- 14 Feb 2023 Planned End Date changed from 1 Sep 2023 to 1 Dec 2023.
- 09 May 2022 Planned End Date changed from 1 Dec 2021 to 1 Sep 2023.